Near future
No Result
View All Result
24 September 2023
  • Home
  • Tech
  • Health
  • Environment
  • Energy
  • Transports
  • Spazio
  • AI
  • concepts
  • H+
Understand, anticipate, improve the future.
CES2023 / Coronavirus / Russia-Ukraine
Near future
  • Home
  • Tech
  • Health
  • Environment
  • Energy
  • Transports
  • Spazio
  • AI
  • concepts
  • H+

Understand, anticipate, improve the future.

No Result
View All Result
Medicine

Coronavirus, lite on Remdesivir. China: "useless". Fauci: "stop it, let's use it".

The FDA's approval for emergency use of Remdesivir is expected for hours. Government consultant Anthony Fauci met journalists in the White House. But it is a clash over effectiveness.

April 29 2020
Gianluca RiccioGianluca Riccio
⚪ 4 minutes
Share34Pin4Tweet12SendShare3ShareShare2
remdesivir jaws fda

READ IN:

In spite of a first Chinese study that advises against its use (and the perplexities of the manufacturer itself), the study center directed by the consultant virologist of the White House presents enthusiastic results on the drug, and approves its emergency use.

Dr. Anthony S. Fauci called a study of an experimental drug against the coronavirus (born for other purposes), Remdesivir, "very optimistic". The FDA plans to announce the urgent use of anti-virus treatment which would show reduced recovery times from the disease.

In these hours, therefore, the FDA announcement of an emergency use authorization of Remdesivir should arrive. Ahead of the announcement, President Trump and Dr. Anthony S. Fauci, the federal government's chief scientist, met with reporters at the White House.

In the press conference, Dr. Fauci warned that the results of the study supervised by the NIAD, the National Institute of Allergy and Infectious Diseases, have yet to be properly revised, but they expressed optimism that it could make a difference.

In China, I have a different opinion

Among the first to experiment with the drug in the field (for obvious reasons) are the Chinese. I was talking about it here some time ago. Well, another study, conducted in China and published in the Lancet, has questioned the value of the drug for the treatment of seriously ill patients. Of course, it left open the possibility that it can be useful for others. However, the research on the latter is incomplete, due to the insufficiency of a congruous number of observers.

The article continues after the related links

To REALLY avoid new pandemics, the fur industry needs to be wiped out

There is never peace for the WHO chief: prepare for a disease more lethal than COVID

Fauci: "reduces recovery times by over a third"

Dr Fauci said Remdesivir could reduce recovery times by about a third. "Although a 31% improvement is not definitive, it is an important signal: because what it has shown is that a drug can block this virus," said Fauci. "This is very encouraging."

Trump echoes him, calling it a good sign. "It is certainly a positive event, it is a very positive event," said the US President.

The producers themselves hold back

In a statement, Gilead Sciences claimed to be "aware of the positive data that emerged" from the study of the institute of Dr. Fauci. Very cautiously, then, the company adds: "We understand that the process has reached its primary endpoint and that NIAID will provide detailed information at an upcoming briefing." An acknowledgment that sounds rather lukewarm. And it is clear why: Remdesivir has not yet obtained a license or approval. Neither in the USA nor anywhere else in the world. "And it has not yet proven to be safe or effective for the treatment of Covid-19," they specify to Gilead herself.

The spokesperson, Ryan McKeel, said the company is unable to predict what actions the federal government will take. "However, we are continuing to discuss with them the growing body of evidence for remdesivir as a potential treatment for COVID-19, with the goal of making remdesivir more widely available to patients in urgent need of treatment." Meanwhile, after the announcement by Fauci, Gilead shares fly into the stock market.

Remdesivir has never been approved as a treatment for any disease. It was developed to combat Ebola, but results from a clinical trial in Africa have also been disappointing.

Expectations have been fueled by anecdotal reports of Covid-19 patients taking Remdesivir and reportedly recovering. Two of these reports were published in the prestigious New England Journal of Medicine, giving credibility to what the researchers later claimed as uncertain results.

Without comparative studies between the drug and a placebo, it was impossible to know whether the drug made a difference or whether patients improved on their own with normal supportive care.

Remdesivir's study published in Lancet found no benefit for the drug over placebo .

"Unfortunately, our study found that while safe and adequately tolerated, remdesivir did not provide significant benefits over placebo," said lead investigator of the new study, Dr. Bin Cao of China-Japan Friendship Hospital and Capital. Beijing Medical University. "This is not the result we were hoping for," he added.

The debate becomes increasingly heated, and confusion on the subject reigns supreme.

Tags: Coronavirusredevive

Latest news

  • All the maps of the future: from research tools to doors to tomorrow
  • The bizarre AI that translates the language of chickens
  • Jeddah Tower, construction site of the one kilometer high skyscraper reopens
  • Spider silk from modified silkworms: stronger than Kevlar and 100% natural
  • VIR-1388, HIV vaccine being tested in the USA and South Africa
  • MOWT, innovative floating hydroelectric for slow-flowing waters
  • CRAFT, what stage is the Chinese project to build an artificial Sun?
  • Remote work, halved emissions
  • Shipping pallets in the digital age: how the Internet has revolutionized the logistics landscape
  • BMW 7 Series Protection: the sedan that defies grenades and flamethrowers


GPT Chat Megaeasy!

Concrete guide for those approaching this artificial intelligence tool, also designed for the school world: many examples of applications, usage indications and ready-to-use instructions for training and interrogating Chat GPT.

To submit articles, disclose the results of a research or scientific discoveries write to the editorial staff

Enter the Telegram channel of Futuroprossimo, click here. Or follow us on Instagram, Facebook, Twitter, Mastodon e LinkedIn.

FacebookTwitterInstagramTelegramLinkedInMastodonPinterestTikTok

The daily tomorrow.


Futuroprossimo.it provides news on the future of technology, science and innovation: if there is something that is about to arrive, here it has already arrived. FuturoProssimo is part of the network ForwardTo, studies and skills for future scenarios.

  • Environment
  • Architecture
  • Artificial intelligence
  • Gadgets
  • concepts
  • Design
  • Medicine
  • Spazio
  • Robotica
  • Work
  • Transports
  • Energy
  • Edition Francaise
  • Deutsche Ausgabe
  • Japanese version
  • English Edition
  • Portuguese Edition
  • Read more
  • Spanish edition

Subscribe to our newsletter

  • The Editor
  • Advertising on FP
  • Privacy Policy

© 2023 Near future - Creative Commons License
This work is distributed under license Creative Commons Attribution 4.0 International.

No Result
View All Result
Understand, anticipate, improve the future.
  • Home
  • Tech
  • Health
  • Environment
  • Energy
  • Transports
  • Spazio
  • AI
  • concepts
  • H+